Please ensure Javascript is enabled for purposes of website accessibility

CDC Finds Higher-Than-Expected Heart Inflammation Cases in Young Men Following COVID Vaccine Jabs

By Eric Volkman – Jun 10, 2021 at 5:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The patients all received both doses of either the Moderna or Pfizer/BioNTech vaccine.

In a potentially alarming development, the U.S. Centers for Disease Control and Prevention (CDC) said Thursday that young American men are showing notable increases in heart inflammation conditions after receiving their final coronavirus vaccine shot.

That's according to data from a pair of vaccine monitoring systems, which indicate that over 50% of post-inoculation heart inflammation cases occurred in males aged 12 to 24. Meanwhile, people in that demographic received only 9% of the two-shot regimens of the Moderna (MRNA -0.37%) or Pfizer (PFE -2.33%)/BioNTech (BNTX 0.25%) vaccines, so the imbalance is clear.

Young man about to receive a vaccine shot.

Image source: Getty Images.

By far, those heart inflammation cases occurred within one week of the recipients getting their second shot. Other data show that the median age of vaccinated individuals who developed heart inflammation following their final dose was 24.

The CDC is convening a meeting of its advisory committee on immunization practices next week to review the evidence and evaluate the risk of such conditions.

In a media statement, Pfizer wrote, "It is important to understand that a careful assessment of the reports is ongoing and it has not been concluded that the mRNA COVID-19 vaccines cause myocarditis or pericarditis." 

The company has also pointed out that "the number of reports is small given the number of doses administered." All told, around 130 million Americans have been fully inoculated with either the Moderna or Pfizer/BioNTech vaccine.

In an article on the development published Thursday by Reuters, the news agency wrote that Moderna said it hasn't established a causal association between heart inflammation and the administration of mRNA-1273, its coronavirus vaccine.

Investors in the three affected companies had mixed reactions to the news. Shares of Moderna and BioNTech slumped on the day, against the S&P 500's 0.5% growth, while Pfizer rose by 2.2%.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$125.15 (-0.37%) $0.47
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$43.09 (-2.33%) $-1.03
BioNTech SE Stock Quote
BioNTech SE
BNTX
$137.53 (0.25%) $0.34

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.